Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (611-620 of 643) with videos related to

Pageof 65
Sort By:
The Journal of Clinical Investigation|June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer modelsMei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Cancer Metastasis Reviews|December 28, 2016
Patient-derived xenograft (PDX) models in basic and translational breast cancer researchLacey E Dobrolecki, Susie D Airhart, Denis G Alferez, et al.
Molecular Cancer Therapeutics|April 19, 2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus RecommendationsFunda Meric-Bernstam, Michael W Lloyd, Soner Koc, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
Pageof 65

Showing results (611-620 of 643) with videos related to

Sort By:
Pageof 65
The Journal of Clinical Investigation|June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer modelsMei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Cancer Metastasis Reviews|December 28, 2016
Patient-derived xenograft (PDX) models in basic and translational breast cancer researchLacey E Dobrolecki, Susie D Airhart, Denis G Alferez, et al.
Molecular Cancer Therapeutics|April 19, 2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus RecommendationsFunda Meric-Bernstam, Michael W Lloyd, Soner Koc, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
Pageof 65